GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (STU:1CG) » Definitions » Beginning Cash Position

CRISPR Therapeutics AG (STU:1CG) Beginning Cash Position : €369.0 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Beginning Cash Position?

CRISPR Therapeutics AG's Beginning Cash Position for the quarter that ended in Mar. 2024 was €369.0 Mil.

CRISPR Therapeutics AG's quarterly Beginning Cash Position increased from Sep. 2023 (€427.8 Mil) to Dec. 2023 (€494.8 Mil) but then declined from Dec. 2023 (€494.8 Mil) to Mar. 2024 (€369.0 Mil).

CRISPR Therapeutics AG's annual Beginning Cash Position declined from Dec. 2021 (€1,049.1 Mil) to Dec. 2022 (€887.3 Mil) and declined from Dec. 2022 (€887.3 Mil) to Dec. 2023 (€205.5 Mil).


CRISPR Therapeutics AG Beginning Cash Position Historical Data

The historical data trend for CRISPR Therapeutics AG's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Beginning Cash Position Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 413.83 779.92 1,049.14 887.31 205.46

CRISPR Therapeutics AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.27 328.70 427.83 494.81 368.98

CRISPR Therapeutics AG Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


CRISPR Therapeutics AG Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG (STU:1CG) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (STU:1CG) Headlines

No Headlines